Millipore Sigma Vibrant Logo

119140 Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem

119140
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
119140-10MG
Récupération des données relatives à la disponibilité...
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Flacon en verre 10 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
      Catalogue Number119140
      Brand Family Calbiochem®
      Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
      References
      ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
      de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
      Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
      Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
      Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
      Cusack, N., et al. 1981. Br J Pharm.72, 443.
      Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
      Product Information
      CAS number35920-39-9
      FormWhite solid
      Hill FormulaC₁₂H₁₆N₆O₄
      Chemical formulaC₁₂H₁₆N₆O₄
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Target K<sub>i</sub>14 nM
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      119140

      Références bibliographiques

      Aperçu de la référence bibliographique
      Forster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
      de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
      Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
      Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
      Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
      Cusack, N., et al. 1981. Br J Pharm.72, 443.
      Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision25-September-2019 JSW
      Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
      DescriptionA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number35920-39-9
      Chemical formulaC₁₂H₁₆N₆O₄
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (50 mM)
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
      de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
      Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
      Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
      Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
      Cusack, N., et al. 1981. Br J Pharm.72, 443.
      Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.